

Supporting information

Pimarane-derived diterpenoids with anti-*Helicobacter pylori* activity from the tuber of *Icacina trichantha*†

Ming-Ming Xu,^{‡a} Junfei Zhou,^{‡a} Liping Zeng,^{‡b} Jingchen Xu,^b Monday M. Onakpa,^c Jin-Ao Duan,^a Chun-Tao Che,^d Hong kai Bi,^{*b} and Ming Zhao,^{*a}

^a*Jiangsu Collaborative Innovation Centre of Chinese Medicinal Resources Industrialization, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, P. R. China. E-mail: mingzhao@njucm.edu.cn*

^b*Department of Pathogen Biology, Jiangsu Key Laboratory of Pathogen Biology, Nanjing Medical University, Nanjing 211166, P. R. China. E-mail: hkbi@njmu.edu.cn*

^c*Department of Veterinary Pharmacology and Toxicology, University of Abuja, Abuja 920001, Nigeria*


^d*Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States*

Contents

Fig. S1 Flow chart of extraction and isolation.....	4
Table S1 Antibacterial activity results of EtOAc and H ₂ O fractions and the main subfractions from tubers of <i>I. trichantha</i> against twelve bacterial species (MIC: µg/ml).....	5
Table S2 Antibacterial activity results of compounds 1–12 isolated from tubers of <i>I. trichantha</i> against a series of bacterial species (MIC: µg/ml).....	5
Table S3 ¹ H [δ , mult (<i>J</i> in Hz)] and ¹³ C NMR spectroscopic data for 1 in chloroform- <i>d</i> and 2 in DMSO- <i>d</i> ₆	6
Table S4 GIAO ¹³ C NMR calculation of structure 1a and 1b.....	7
Table S5 Fractional inhibitory concentration (FIC) and interaction style of icacinlactone B (6) combined with four antibiotics against <i>H. pylori</i> strain G27.....	8
Table S6 Fractional inhibitory concentration (FIC) and interaction style of icacinlactone B (6) combined with four antibiotics against of <i>H. pylori</i> strain HP159.....	8
Table S7 Cartesian coordinate for the lowest energy conformer of 1 calculated at TD/B3LYP/6-311++G(d,p) level of theory in gas phase.....	9
Table S8 Cartesian coordinate for the lowest energy conformer of the aglycon of 2 calculated at B3LYP/6-31+G(d) level of theory in gas phase.....	11
Fig. S2 ¹ H NMR (400 MHz, chloroform- <i>d</i>) spectrum of compound 1.....	12
Fig. S3 ¹³ C NMR (100 MHz, chloroform- <i>d</i>) spectrum of compound 1.....	12
Fig. S4 DEPT135 (100 MHz, chloroform- <i>d</i>) spectrum of compound 1.....	13
Fig. S5 ¹ H– ¹ H COSY spectrum (400 MHz, chloroform- <i>d</i>) of compound 1.....	13
Fig. S6 HSQC spectrum (chloroform- <i>d</i>) of compound 1 (¹ H: 400 MHz, ¹³ C: 100 MHz).....	14
Fig. S7 HMBC spectrum (chloroform- <i>d</i>) of compound 1 (¹ H: 400 MHz, ¹³ C: 100 MHz).....	14
Fig. S8 NOESY spectrum (400 MHz, chloroform- <i>d</i>) of compound 1.....	15
Fig. S9 IR spectrum of compound 1.....	15
Fig. S10 (+)-HR-ESI-MS spectrum of compound 1.....	16
Fig. S11 UV spectrum of compound 1.....	16
Fig. S12 ¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) spectrum of compound 2.....	17
Fig. S13 ¹³ C NMR (125 MHz, DMSO- <i>d</i> ₆) spectrum of compound 2.....	17
Fig. S14 DEPT135 (125 MHz, DMSO- <i>d</i> ₆) spectrum of compound 2.....	18
Fig. S15 ¹ H– ¹ H COSY spectrum (500 MHz, DMSO- <i>d</i> ₆) of compound 2.....	18
Fig. S16 HSQC spectrum (DMSO- <i>d</i> ₆) of compound 2 (¹ H: 500 MHz, ¹³ C: 125 MHz).....	19
Fig. S17 HMBC spectrum (DMSO- <i>d</i> ₆) of compound 2 (¹ H: 500 MHz, ¹³ C: 125 MHz).....	19
Fig. S18 NOESY spectrum (500 MHz, DMSO- <i>d</i> ₆) of compound 2.....	20
Fig. S19 IR spectrum of compound 2.....	20
Fig. S20 (–)-HR-ESI-MS spectrum of compound 2.....	21
Fig. S21 UV spectrum of compound 2.....	21

Fig. S22 ¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) spectrum of compound 3.....	22
Fig. S23 ¹³ C NMR (125 MHz, DMSO- <i>d</i> ₆) spectrum of compound 3.....	22
Fig. S24 ¹ H NMR (500 MHz, CD ₃ OD- <i>d</i> ₄) spectrum of compound 4.....	23
Fig. S25 ¹³ C NMR (125 MHz, CD ₃ OD- <i>d</i> ₄) spectrum of compound 4.....	23
Fig. S26 ¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) spectrum of compound 5.....	24
Fig. S27 ¹³ C NMR (125 MHz, DMSO- <i>d</i> ₆) spectrum of compound 5.....	24
Fig. S28 ¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) spectrum of compound 6.....	25
Fig. S29 ¹³ C NMR (125 MHz, DMSO- <i>d</i> ₆) spectrum of compound 6.....	25
Fig. S30 ¹ H NMR (500 MHz, Pyridine- <i>d</i> ₅) spectrum of compound 7.....	26
Fig. S31 ¹³ C NMR (125 MHz, pyridine- <i>d</i> ₅) spectrum of compound 7.....	26
Fig. S32 ¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) spectrum of compound 8.....	27
Fig. S33 ¹³ C NMR (125 MHz, DMSO- <i>d</i> ₆) spectrum of compound 8.....	27
Fig. S34 ¹ H NMR (500 MHz, Pyridine- <i>d</i> ₅) spectrum of compound 9.....	28
Fig. S35 ¹³ C NMR (125 MHz, Pyridine- <i>d</i> ₅) spectrum of compound 9.....	28
Fig. S36 ¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) spectrum of compound 10.....	29
Fig. S37 ¹³ C NMR (125 MHz, DMSO- <i>d</i> ₆) spectrum of compound 10.....	29
Fig. S38 ¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) spectrum of compound 11.....	30
Fig. S39 ¹³ C NMR (125 MHz, DMSO- <i>d</i> ₆) spectrum of compound 11.....	30
Fig. S40 ¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) spectrum of compound 12.....	31
Fig. S41 ¹³ C NMR (125 MHz, DMSO- <i>d</i> ₆) spectrum of compound 12.....	31
Fig. S42 HPLC chromatogram of the derivative of the standard L-Glucose.....	32
Fig. S43 HPLC chromatogram of the derivative of the standard D-Glucose.....	32
Fig. S44 HPLC chromatogram of derivative of the hydrolysate of compound 2.....	32

Fig. S1 Flow chart of extraction and isolation.



MC2 155	16	/	/	>128	>128	>128	>128	>128	>128	>128	>128	>128	>128
ATCC1943	2	/	/	>128	/	/	>128	/	/	/	/	/	/
4													
FA2-2	4	/	/	>128	/	/	>128	/	/	/	/	/	/
168	4	/	/	128	/	/	>128	/	/	/	/	/	/
ATCC6538	0.5	/	/	>128	/	/	>128	/	/	/	/	/	/

^a MICs of MTZ are determined against *Helicobacter* and non-*Helicobacter* species, respectively.

^b MTZ, metronidazole.

NA: No Inhibition.

Table S3 ¹H [δ , mult (J in Hz)] and ¹³C NMR spectroscopic data for **1** in chloroform-*d* and **2** in DMSO-*d*₆

no.	1		2	
	δ_{H} (J in Hz)	δ_{C}	δ_{H} (J in Hz)	δ_{C}
1 α	2.38, ddd (13.4, 9.8, 3.3)	40.8	1.66, m	36.4
1 β	2.54, dd (13.8, 2.8)		1.44, m	
2 α	4.38 dd (7.2, 9.6)	65.9	2.17, m	28.7
2 β			1.68, m	
3		96.8	3.42, dd (10.9, 5.6)	84.3
4		48.4		45.9
5	2.26, m	51.7	1.52, d (3.0)	45.7
6	5.13, ddd (9.8, 7.9, 5.7)	74.7	4.01, t (3.6)	62.6
7 α	4.11, m	25.7	1.57, td (13.6, 2.4)	33.3
7 β	2.97, dd (17.2, 5.7)		1.89, m	
8		109.2	3.06, m	28.9
9		132.7	1.43, m	37.8
10		36.0		33.2
11 α	6.56, s	100.1	1.80, dd (11.5, 5.7)	17.0
11 β			1.16, m	
12 α		151.8	2.17, m	17.8
12 β			1.97, ddt (18.7, 11.5, 6.0)	
13		118.0		111.3
14		153.8		192.1
15 α	6.34, s	100.6		200.1
15 β				
16		161.1	4.57, d (5.5)	74.9
18	1.45, s	19.6	1.29, s	17.4
19		179.6		171.8
20 α	3.90, d (2.6)	70.7	4.51, d (11.3)	77.3
20 β	4.16, dd (6.8, 2.6)		3.87, d (11.3)	
12-OCH3	3.93, s	55.7		
1' α	1.88, m	36.6	4.19, d (7.8)	104.5
1' β	1.10, m			
2' α	1.52, m	19.4	3.06, m	76.8
2' β	1.85, m			
3' α	2.13, m	37.1	3.06, m	76.9
3' β	0.96, m			
4'		43.3	2.94, td (8.5, 4.2)	73.9
5' α	1.60, dd (11.8, 2.6)	48.3	3.06, m	70.0
6' α	2.22, m	26.2	3.64, m	61.1
6' β			3.42, dd (10.9, 5.6)	
7'	3.45, d (5.8)	41.6		
8'		122.9		
9'		140.3		
10'		38.9		
11' α	0.93, m	20.8		
11' β	2.13, m			

12 ^α	1.77, m	30.5
12 ^β	1.69, m	
13 ^γ		44.3
14 ^α	2.26, m	37.5
14 ^β	1.92, m	
15 ^γ		214.8
16 ^γ	4.33, brd (16.8)	64.1
17 ^γ	1.14, s	20.7
18 ^γ	0.97, s	28.5
19 ^γ		183.2
20 ^γ	0.93, s	17.5

Table S4 GIAO ¹³C NMR calculation of structure **1a** and **1b**

no.	exptl. δ_C	calcd δ_C 1a	deviation	calcd δ_C 1b	deviation
1	40.8	40.8	0.0	41.0	0.2
2	65.9	66.1	0.2	66.1	0.2
3	96.8	96.3	-0.5	96.7	-0.1
4	48.4	50.2	1.8	50.1	1.7
5	51.7	53.5	1.8	53.7	2.0
6	74.7	75.3	0.6	75.3	0.6
7	25.7	25.3	-0.4	23.8	-1.9
8	109.2	108.5	-0.7	107.2	-2.0
9	132.7	136.3	3.6	135.4	2.7
10	36.0	35.5	-0.5	34.7	-1.3
11	100.1	97.1	-3.0	100.5	0.4
12	151.8	148.9	-2.9	148.5	-3.3
13	118.0	115.8	-2.2	113.2	-4.8
14	153.8	152.6	-1.2	152.3	-1.5
15	100.6	102.2	1.6	103.7	3.1
16	161.1	162.6	1.5	160.6	-0.5
18	19.6	17.4	-2.2	17.8	-1.8
19	179.6	178.6	-1.0	177.1	-2.5
20	70.7	68.7	-2.9	68.7	-2.9
12-OCH ₃	55.7	56.1	0.4	56.3	0.6
1 ^γ	36.6	36.6	0.0	35.5	-1.1
2 ^γ	19.4	16.9	-2.5	16.6	-2.8
3 ^γ	37.1	37.9	0.8	39.6	2.5
4 ^γ	43.3	44.5	1.2	43.4	0.1
5 ^γ	48.3	49.8	1.5	49.7	1.4
6 ^γ	26.2	26.2	0.0	25.4	-0.8
7 ^γ	41.6	42.4	0.8	41.8	0.2
8 ^γ	122.9	125.8	2.9	124.4	1.5
9 ^γ	140.3	144.0	3.7	146.9	6.6
10 ^γ	38.9	40.0	1.1	40.5	1.6
11 ^γ	20.8	21.6	0.8	23.0	2.2
12 ^γ	30.5	31.2	0.7	32.7	2.2
13 ^γ	44.3	45.3	1.0	47.5	3.2
14 ^γ	37.5	39.4	1.9	40.2	2.7
15 ^γ	214.8	214.5	-0.3	218.0	3.2
16 ^γ	64.1	62.4	-1.7	61.8	-2.3
17 ^γ	20.7	21.0	0.3	19.1	-1.6

18'	28.5	26.8	-1.7	26.5	-2.0
19'	183.2	181.3	-1.9	179.9	-3.3
20'	17.5	14.5	-3.0	15.1	-2.4
		MAE	1.4	MAE	1.9
		RMS	1.8	RMS	2.3
		sDP4+	100%	sDP4+	0%

Table S5 Fractional inhibitory concentration (FIC) and interaction style of icacinlactone B (**6**) combined with four antibiotics against *H. pylori* strain G27

	MIC of 6 (µg/mL)		MIC of MTZ (µg/mL)		MIC of CLR (µg/mL)		MIC of AMX (µg/mL)		MIC of LVX (µg/mL)		FICI	Interaction
	Alone	Combination	Alone	Combination	Alone	Combination	Alone	Combination	Alone	Combination		
6 + MTZ	8	4	2	0.5							0.75	additive effect
6 + CLR	8	2			0.008	0.004					0.75	additive effect
6 + AMX	8	2					0.125	0.125			1.25	indifference
6 + LVX	8	4							0.25	0.25	1.5	indifference

FIC of **6** = MIC of **6** in combination with antibiotic/MIC of **6** alone.

FIC of antibiotic = MIC of antibiotic in combination with **6**/MIC of antibiotic alone.

FIC index = FIC of **6**+ FIC of antibiotic.

FICI ≤ 0.5, synergy; 0.5 < FICI ≤ 1, additive effect; 1 < FICI ≤ 2, indifference; FICI > 4.0, antagonism.

(CLR: clarithromycin, AMX: amoxicillin, MTZ: metronidazole; LVX: levofloxacin)

Table S6 Fractional inhibitory concentration (FIC) and interaction style of icacinlactone B (**6**) combined with four antibiotics against of *H. pylori* strain HP159

	MIC of 6 (µg/mL)		MIC of MTZ (µg/mL)		MIC of CLR (µg/mL)		MIC of AMX (µg/mL)		MIC of LVX (µg/mL)		FICI	Interaction
	Alone	Combination	Alone	Combination	Alone	Combination	Alone	Combination	Alone	Combination		
6 + MTZ	8	4	16	1							0.56	additive effect
6 + CLR	8	2			2	1					0.75	additive effect
6 + AMX	8	4					0.125	0.008			0.56	indifference
6 + LVX	8	2							8	8	1.25	indifference

FIC of **6** = MIC of **6** in combination with antibiotic/MIC of **6** alone.

FIC of antibiotic = MIC of antibiotic in combination with **7**/MIC of antibiotic alone.

FIC index = FIC of **6** + FIC of antibiotic.

FICI ≤ 0.5, synergy; 0.5 < FICI ≤ 1, additive effect; 1 < FICI ≤ 2, indifference; FICI > 4.0, antagonism.

(CLR: clarithromycin, AMX: amoxicillin, MTZ: metronidazole; LVX: levofloxacin)

Table S7 Cartesian coordinate for the lowest energy conformer of **1** calculated at TD/B3LYP/6-311++G(d,p) level of theory in gas phase

Center number	Atomic number	Atomic type	Coordinates (Angstroms)		
			X	Y	Z
1	6	0	6.829779	-1.77288	1.554311
2	6	0	6.075429	-2.96861	0.966137
3	6	0	5.354024	-2.63176	-0.37258
4	6	0	4.48147	-1.34189	-0.15448
5	6	0	5.204936	-0.09872	0.456368
6	6	0	6.252689	0.579895	-0.47069
7	6	0	3.664225	-0.93802	-1.38853
8	6	0	2.546942	0.058417	-1.01977
9	6	0	2.98682	1.078739	0.038455
10	6	0	4.13336	0.982014	0.742511
11	6	0	2.012621	2.233031	0.225803
12	6	0	2.648605	3.487657	0.849337
13	6	0	3.392462	3.039371	2.115738
14	6	0	4.487818	2.008432	1.810704
15	6	0	1.557077	4.526167	1.202456
16	6	0	3.618198	4.192816	-0.10867
17	6	0	3.350322	4.219227	-1.61506
18	8	0	4.259748	5.056333	-2.27228
19	8	0	4.598445	4.79804	0.300425
20	1	0	3.765578	-1.64064	0.620675
21	6	0	5.910942	-0.5603	1.760922
22	6	0	6.356814	-2.55542	-1.53981
23	6	0	-2.27294	-0.35503	-0.34684
24	6	0	-3.16033	-1.3393	0.135953
25	6	0	-0.92733	-0.71053	-0.34715
26	6	0	-0.421	-1.94304	0.091172
27	6	0	-1.32806	-2.90309	0.565017
28	6	0	-2.68568	-2.5864	0.58225
29	8	0	0.107632	0.081474	-0.77817
30	6	0	1.276361	-0.64592	-0.60502
31	6	0	1.008831	-1.87299	-0.08465
32	8	0	-0.94047	-4.13283	1.01544
33	6	0	-2.75528	0.985792	-0.85404
34	1	0	0.024604	-4.20757	0.948981
35	6	0	-5.23076	-1.07797	-1.27833
36	6	0	-4.77743	0.472346	0.699867
37	6	0	-5.55152	-1.85349	1.038446
38	1	0	-3.37051	-3.33766	0.957947
39	1	0	-1.92623	1.699118	-0.87554
40	1	0	-3.10986	0.906263	-1.88949
41	1	0	-4.48953	0.434261	1.75549
42	6	0	-6.22792	0.980195	0.539459
43	6	0	-3.91459	1.540767	-0.00736
44	8	0	-4.8205	2.301221	-0.85409
45	1	0	-3.52532	2.247901	0.732907
46	6	0	-7.03104	-1.43336	0.839462
47	6	0	4.352812	-3.7778	-0.59981
48	8	0	3.458047	-4.07718	0.170577
49	8	0	4.540019	-4.46627	-1.74759
50	1	0	-5.25325	-1.76787	2.089461
51	1	0	-5.48154	-2.90838	0.7588
52	1	0	7.681004	-1.5044	0.916484
53	1	0	7.261551	-2.06526	2.519639
54	1	0	6.758846	-3.81344	0.809569
55	1	0	5.318045	-3.30044	1.685978

56	1	0	1.740016	-2.63581	0.144436
57	1	0	6.530956	1.557682	-0.06503
58	1	0	4.314155	-0.47437	-2.1376
59	1	0	3.218176	-1.81331	-1.87417
60	1	0	2.281948	0.624322	-1.92596
61	1	0	1.546356	2.471177	-0.73835
62	1	0	1.175194	1.92217	0.865876
63	1	0	2.649038	2.603658	2.79601
64	1	0	3.833887	3.900903	2.625993
65	1	0	5.404844	2.537816	1.520033
66	1	0	4.735669	1.488655	2.743465
67	1	0	2.001522	5.427976	1.63658
68	1	0	0.972857	4.820637	0.322916
69	1	0	0.86477	4.098484	1.936643
70	1	0	3.420547	3.184637	-1.99066
71	1	0	2.315309	4.548583	-1.79861
72	1	0	4.88206	5.345016	-1.57478
73	1	0	5.147158	-0.82353	2.506702
74	1	0	6.495547	0.263251	2.18552
75	1	0	5.873545	-2.2699	-2.47837
76	1	0	6.827503	-3.52957	-1.69926
77	1	0	7.149999	-1.83523	-1.33722
78	6	0	-4.63804	-0.97706	0.149969
79	6	0	-7.08178	-0.1768	-0.05107
80	6	0	-6.11496	2.044604	-0.55443
81	6	0	-6.82472	1.609372	1.808916
82	8	0	-8.41333	0.171625	-0.24657
83	8	0	-6.53233	-0.48321	-1.33626
84	8	0	-7.7227	-2.49669	0.205939
85	1	0	-5.30248	-2.13713	-1.55877
86	1	0	-7.50484	-1.19715	1.803269
87	1	0	-4.61107	-0.57482	-2.02531
88	1	0	-8.40943	0.979143	-0.79974
89	1	0	-8.51415	-2.10277	-0.20092
90	1	0	-7.82315	2.004533	1.60688
91	1	0	3.854173	-5.16167	-1.75696
92	1	0	-6.1942	2.431184	2.167973
93	1	0	-6.90139	0.871572	2.613876
94	8	0	-7.0373	2.605833	-1.10206
95	1	0	5.863033	0.750949	-1.4779
96	1	0	7.17599	0.003279	-0.56038

Table S8 Cartesian coordinate for the lowest energy conformer of the aglycon of **2** calculated at B3LYP/6-31+G(d) level of theory in gas phase

Center number	Atomic number	Atomic type	Coordinates (Angstroms)		
			X	Y	Z
1	6	0	-2.83256	2.128613	0.264403
2	6	0	-3.39871	1.145552	-0.76727
3	6	0	-2.78713	-0.2977	-0.59803
4	6	0	-1.24051	-0.18657	-0.73413
5	6	0	-0.68312	0.688788	0.421339
6	6	0	-1.29684	2.106734	0.27493
7	6	0	-0.54171	-1.54937	-0.90266
8	6	0	0.978748	-1.38935	-0.97652
9	6	0	1.533706	-0.64717	0.259584
10	6	0	0.889805	0.761918	0.447419
11	6	0	3.017361	-0.512	0.171859
12	6	0	3.712198	0.628719	-0.06159
13	6	0	3.050591	1.957085	-0.25954
14	6	0	1.539289	1.782357	-0.52324
15	8	0	3.767524	-1.63598	0.324511
16	6	0	5.152507	-1.23625	0.18346
17	6	0	5.124284	0.279805	-0.07255
18	8	0	6.111844	0.981933	-0.24715
19	8	0	-4.81827	1.150287	-0.76831
20	6	0	-1.10741	0.071034	1.773338
21	8	0	-2.46295	-0.41947	1.864513
22	6	0	-3.22371	-0.74046	0.799701
23	8	0	-4.32196	-1.22471	1.002988
24	6	0	-3.39588	-1.22988	-1.65952
25	1	0	1.158092	1.10008	1.461808
26	1	0	1.317695	-1.27351	1.133861
27	1	0	-1.04478	0.346056	-1.67781
28	8	0	-0.93005	-2.39315	0.191428
29	1	0	-3.18858	3.134963	0.015525
30	1	0	-3.23874	1.893973	1.255738
31	1	0	-3.11841	1.480684	-1.77537
32	1	0	-0.91649	2.757332	1.074602
33	1	0	-0.9529	2.540738	-0.67119
34	1	0	-0.88973	-1.99746	-1.84271
35	1	0	1.451958	-2.37611	-1.05646
36	1	0	1.235952	-0.84496	-1.89487
37	1	0	3.519856	2.495733	-1.09221
38	1	0	3.203373	2.588885	0.628195
39	1	0	1.385222	1.467137	-1.56434
40	1	0	1.0662	2.761606	-0.42143
41	1	0	5.591142	-1.7862	-0.65429
42	1	0	5.682773	-1.48872	1.106278
43	1	0	-1.03372	0.823975	2.565642
44	1	0	-0.47533	-0.77583	2.041994
45	1	0	-3.13322	-2.27423	-1.47233
46	1	0	-4.48346	-1.15463	-1.66035
47	1	0	-3.03429	-0.94412	-2.65561
48	1	0	-0.67548	-3.30944	0.002801
49	1	0	-5.14178	0.591711	-0.03735

Fig. S2 ^1H NMR (400 MHz, chloroform-*d*) spectrum of compound **1**




Fig. S3 ^{13}C NMR (100 MHz, chloroform-*d*) spectrum of compound **1**




Fig. S4 DEPT135 (100 MHz, chloroform-*d*) spectrum of compound **1**




Fig. S5 ^1H - ^1H COSY spectrum (400 MHz, chloroform-*d*) of compound **1**




Fig. S6 HSQC spectrum (chloroform-*d*) of compound **1** (^1H : 400 MHz, ^{13}C : 100 MHz)




Fig. S7 HMBC spectrum (chloroform-*d*) of compound **1** (^1H : 400 MHz, ^{13}C : 100 MHz)




Fig. S8 NOESY spectrum (400 MHz, chloroform-*d*) of compound **1**




Fig. S9 IR spectrum of compound **1**




Fig. S10 (+)-HR-ESI-MS spectrum of compound **1**

xumingming-20210109-19 218 (5.204)




Fig. S11 UV spectrum of compound **1**




Fig. S12 ^1H NMR (500 MHz, $\text{DMSO-}d_6$) spectrum of compound **2**




Fig. S13 ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) spectrum of compound **2**




Fig. S14 DEPT135 (125 MHz, DMSO-*d*₆) spectrum of compound **2**




Fig. S15 ¹H-¹H COSY spectrum (500 MHz, DMSO-*d*₆) of compound **2**




Fig. S16 HSQC spectrum (DMSO-*d*₆) of compound **2** (¹H: 500 MHz, ¹³C: 125 MHz)




Fig. S17 HMBC spectrum (DMSO-*d*₆) of compound **2** (¹H: 500 MHz, ¹³C: 125 MHz)




Fig. S18 NOESY spectrum (500 MHz, DMSO- d_6) of compound **2**




Fig. S19 IR spectrum of compound **2**




Fig. S20 (-)-HR-ESI-MS spectrum of compound **2**




Fig. S21 UV spectrum of compound **2**




Fig. S22 ^1H NMR (500 MHz, $\text{DMSO-}d_6$) spectrum of compound **3**




Fig. S23 ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) spectrum of compound **3**

IT-18-2.1.fid




Fig. S24 ^1H NMR (500 MHz, $\text{CD}_3\text{OD}-d_4$) spectrum of compound **4**




Fig. S25 ^{13}C NMR (125 MHz, $\text{CD}_3\text{OD}-d_4$) spectrum of compound **4**




Fig. S26 ^1H NMR (500 MHz, $\text{DMSO-}d_6$) spectrum of compound **5**




Fig. S27 ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) spectrum of compound **5**




Fig. S28 ^1H NMR (500 MHz, $\text{DMSO-}d_6$) spectrum of compound **6**




Fig. S29 ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) spectrum of compound **6**




Fig. S30 ^1H NMR (500 MHz, Pyridine- d_5) spectrum of compound **7**




Fig. S31 ^{13}C NMR (125 MHz, pyridine- d_5) spectrum of compound **7**




Fig. S32 ^1H NMR (500 MHz, $\text{DMSO-}d_6$) spectrum of compound **8**




Fig. S33 ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) spectrum of compound **8**




Fig. S34 ^1H NMR (500 MHz, Pyridine- d_5) spectrum of compound **9**




Fig. S35 ^{13}C NMR (125 MHz, Pyridine- d_5) spectrum of compound **9**




Fig. S36 ^1H NMR (500 MHz, $\text{DMSO-}d_6$) spectrum of compound **10**




Fig. S37 ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) spectrum of compound **10**




Fig. S38 ^1H NMR (500 MHz, $\text{DMSO-}d_6$) spectrum of compound **11**




Fig. S39 ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) spectrum of compound **11**




Fig. S40 ^1H NMR (500 MHz, $\text{DMSO-}d_6$) spectrum of compound **12**




Fig. S41 ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) spectrum of compound **12**




Fig. S42 HPLC chromatogram of the derivative of the standard L-Glucose




Fig. S43 HPLC chromatogram of the derivative of the standard D-Glucose




Fig. S44 HPLC chromatogram of derivative of the hydrolysate of compound 2.

